within Pharmacolibrary.Drugs.ATC.C;

model C08CA13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.030000000000000002,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Lercanidipine is a dihydropyridine calcium channel blocker used for the management of mild to moderate essential hypertension. It is approved and widely used orally as an antihypertensive agent due to its long duration of action and reduced incidence of adverse effects compared to older calcium antagonists.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration in fasting conditions.</p><h4>References</h4><ol><li><p>Hanauer Schaab, E, et al., &amp; Barbosa Coelho, E (2020). Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. <i>Journal of clinical pharmacology</i> 60(1) 75–85. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1485&quot;>10.1002/jcph.1485</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31353479/&quot;>https://pubmed.ncbi.nlm.nih.gov/31353479</a></p></li><li><p>McClellan, KJ, &amp; Jarvis, B (2000). Lercanidipine: a review of its use in hypertension. <i>Drugs</i> 60(5) 1123–1140. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200060050-00009&quot;>10.2165/00003495-200060050-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11129125/&quot;>https://pubmed.ncbi.nlm.nih.gov/11129125</a></p></li><li><p>Jabor, VA, et al., &amp; Lanchote, VL (2004). Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 813(1-2) 343–346. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2004.09.038&quot;>10.1016/j.jchromb.2004.09.038</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15556551/&quot;>https://pubmed.ncbi.nlm.nih.gov/15556551</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08CA13;
